BeOne Medicines (ONC) CEO sells 283,154 ADS under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. CEO John Oyler exercised options to acquire 283,154 American Depositary Shares (ADS) and sold the same number on July 15–16, 2026 at weighted average prices from $310.0201 to $323.5858 per ADS under a Rule 10b5-1 trading plan adopted March 10, 2026.
After the trades, he reported no directly held ADS and held 5,445,917 ordinary shares directly as of July 15, 2026, plus indirect positions via trusts and an IRA, including holdings for which he disclaims beneficial ownership, and 1,282,034 share options with a $9.23 exercise price.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 283,154 shares ($89,351,598)
Net Sell
33 txns
Insider
OYLER JOHN
Role
Chief Executive Officer
Sold
283,154 shs ($89.35M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) | 1,254,513 | $0.00 | -- |
| Exercise | Share Option (Right to Buy) | 911,248 | $0.00 | -- |
| Exercise | American Depositary Shares | 96,501 | $160.40 | $15.48M |
| Exercise | American Depositary Shares | 70,096 | $119.96 | $8.41M |
| Sale | American Depositary Shares | 233 | $311.98 | $73K |
| Sale | American Depositary Shares | 4,881 | $314.0772 | $1.53M |
| Sale | American Depositary Shares | 9,516 | $314.7318 | $2.99M |
| Sale | American Depositary Shares | 19,752 | $316.00 | $6.24M |
| Sale | American Depositary Shares | 32,224 | $316.8173 | $10.21M |
| Sale | American Depositary Shares | 42,798 | $317.7887 | $13.60M |
| Sale | American Depositary Shares | 6,402 | $318.5493 | $2.04M |
| Sale | American Depositary Shares | 15,097 | $319.993 | $4.83M |
| Sale | American Depositary Shares | 20,505 | $320.998 | $6.58M |
| Sale | American Depositary Shares | 13,109 | $321.6127 | $4.22M |
| Sale | American Depositary Shares | 1,560 | $322.7076 | $503K |
| Sale | American Depositary Shares | 520 | $323.5858 | $168K |
| Exercise | Share Option (Right to Buy) | 462,865 | $0.00 | -- |
| Exercise | Share Option (Right to Buy) | 996,801 | $0.00 | -- |
| Exercise | Share Option (Right to Buy) | 55,575 | $0.00 | -- |
| Exercise | American Depositary Shares | 35,605 | $100.04 | $3.56M |
| Exercise | American Depositary Shares | 76,677 | $169.58 | $13.00M |
| Exercise | American Depositary Shares | 4,275 | $160.40 | $686K |
| Sale | American Depositary Shares | 6,067 | $310.0201 | $1.88M |
| Sale | American Depositary Shares | 41,336 | $310.9228 | $12.85M |
| Sale | American Depositary Shares | 12,857 | $311.7123 | $4.01M |
| Sale | American Depositary Shares | 48,657 | $312.8583 | $15.22M |
| Sale | American Depositary Shares | 7,640 | $313.5793 | $2.40M |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 0 shares (Direct);
American Depositary Shares — 96,501 shares (Direct);
Ordinary Shares — 5,445,917 shares (Direct);
Ordinary Shares — 481,533 shares (Indirect, See Footnote)
Footnotes (1)
- These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.31 to $310.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.35 to $311.34, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.35 to $312.34, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.35 to $313.345, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.36 to $313.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.27 to $314.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.27 to $315.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.28 to $316.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.28 to $317.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.28 to $318.265, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.30 to $319.11, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.36 to $320.34, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.38 to $321.35, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.39 to $322.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.455 to $323.405, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.495 to $323.625, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on June 30, 2018, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. These securities vest over a four-year period as follows: 25% on April 30, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.
Key Figures
ADS sold: 283154 American Depositary Shares
Underlying shares exercised: 3681002 Ordinary Shares
ADS sale price range: $310.0201–$323.5858 per ADS
+4 more
7 metrics
ADS sold
283154 American Depositary Shares
Total ADS sold by CEO John Oyler on July 15–16, 2026
Underlying shares exercised
3681002 Ordinary Shares
Underlying ordinary shares from option exercises coded M
ADS sale price range
$310.0201–$323.5858 per ADS
Range of reported weighted average ADS sale prices
Direct ordinary share holding
5445917 Ordinary Shares
Ordinary shares held directly as of July 15, 2026
Oyler Investment LLC holding
28204115 Ordinary Shares
Ordinary shares held by Oyler Investment LLC; beneficial ownership disclaimed
Roth IRA holding
9545000 Ordinary Shares
Ordinary shares held for John Oyler’s benefit in a Roth IRA PENSCO trust
Remaining options at $9.23
1282034 Share Options
Share options with $9.23 exercise price remaining after July 16, 2026
Key Terms
American Depositary Share, Rule 10b5-1 trading plan, grantor retained annuity trust, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
grantor retained annuity trust financial
"owned by a grantor retained annuity trust, for which the Reporting Person"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did BeOne Medicines (ONC) CEO John Oyler sell in these insider transactions?
John Oyler sold 283,154 American Depositary Shares of BeOne Medicines over July 15–16, 2026. These ADS came from option exercises and were sold in multiple tranches at reported weighted average prices between $310.0201 and $323.5858 per ADS.
At what prices were BeOne Medicines (ONC) ADS sold by John Oyler?
The reported weighted average sale prices ranged from $310.0201 to $323.5858 per ADS. Footnotes state each tranche comprised many trades within narrow price bands, with full price breakdowns available on request from the issuer or the SEC staff.
Were John Oyler’s BeOne Medicines (ONC) sales under a Rule 10b5-1 plan?
Yes. Footnotes state each sale was effected under a Rule 10b5-1 trading plan adopted on March 10, 2026, and the form’s Rule 10b5-1 checkbox is marked. Such pre-arranged plans automate trades according to preset instructions rather than discretionary timing.
What BeOne Medicines (ONC) holdings does John Oyler report after these transactions?
He reports 5,445,917 ordinary shares held directly as of July 15, 2026, plus large indirect ordinary-share positions via trusts and a Roth IRA, including 9,545,000 shares in a Roth IRA account and 28,204,115 shares in Oyler Investment LLC, some with disclaimed beneficial ownership.